Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin.

Marta Karaźniewicz-ŁadaDagmara KrzyżańskaDorota DanielakJanusz RzeźniczakFranciszek GłówkaMarek SłomczyńskiPaweł Burchardt

Published in: European journal of clinical pharmacology (2020)

The CYP2C19*2 allele is the primary determinant of the exposition to the H4 active metabolite of clopidogrel and platelet reactivity in patients co-treated with atorvastatin or rosuvastatin.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
acute coronary syndrome
prognostic factors
peritoneal dialysis
percutaneous coronary intervention